Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Toyoaki Hida"'
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Haiquan Chen, Hui Tian, Feng Li, Qi Wang, Xiaojie Pan, Guibin Qiao, Wenjie Jiao, Marc de Perrot, Yang Liu, Dirk De Ruysscher, Erminia Massarelli, Yuming Zhu, Chun Chen, Shuben Li, Rafael Rosell, Raffaele Califano, Wenhua Liang, Antonio Rossi, Toyoaki Hida, Robert A. Ramirez, Ran Zhong, Tao Jiang, Changhong Liu, Nicolas Guibert, Chengzhi Zhou, Qixun Chen, Shengxiang Ren, Haitao Ma, D. Ross Camidge, Steven H. Lin, Massimo Di Maio, Wei Liu, Jian Hu, Junke Fu, Mariano Provencio, Xiaojing Zhao, Jianxing He, Kaican Cai, Li Wei, Deruo Liu, Yi Zhang, Wolfram C. M. Dempke, Song Zhao, Caicun Zhou, Mara B. Antonoff
Publikováno v:
Translational Lung Cancer Research, 9(6), 2696-2715. AME Publishing Company
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Translational Lung Cancer Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Transl Lung Cancer Res
Lung cancer is the leading cause of cancer-related death worldwide and in China (1). According to the statistics of the National Cancer Center of China, there were 733,300 new cases of non-small cell lung cancer (NSCLC) and approximately 610,200 rela
Autor:
Toyoaki Hida, Teppei Yamaguchi
Publikováno v:
J Thorac Dis
JAMA Oncol
JAMA Oncol
IMPORTANCE: Consolidative programmed death ligand-1 (PD-L) inhibition after chemoradiotherapy improves overall survival and progression-free survival (PFS) for stage III non–small cell lung cancer (NSCLC) and requires safety evaluation for incorpor
Autor:
Takashi Seto, Noboru Yamamoto, Takeharu Yamanaka, Yuichiro Ohe, Makoto Nishio, Tatsuya Yoshida, Toyoaki Hida, Akira Ono, Takayasu Kurata, Kentaro Sakamaki, Hiroaki Okamoto, Miyako Satouchi, Seiji Niho, Koichi Goto, Tetsuo Akimoto
Publikováno v:
Lung Cancer. 141:64-71
Objectives SPECTRA is a multicenter, randomized phase II study of chemotherapy with cisplatin (CDDP) plus S-1 versus CDDP plus pemetrexed (PEM) in combination with thoracic radiotherapy (TRT) for locally advanced non-squamous non-small cell lung canc
Autor:
Takashi Seto, Terufumi Kato, Hiroshige Yoshioka, Nobuyuki Yamamoto, Hiroshi Tanaka, Hisaya Azuma, Isamu Okamoto, Yahui Tian, Toyoaki Hida, Katsuyuki Kiura
Publikováno v:
Future Oncology. 16:49-60
Aim: Acquired resistance to EGFR tyrosine kinase inhibitors is inevitable in non-small-cell lung cancer. To inform subsequent treatment decisions, we retrospectively assessed therapies following afatinib in Japanese patients from LUX-Lung 3. Patients
Autor:
Geoffrey I. Shapiro, Liza C. Villaruz, Jeffrey W. Clark, Alexander Drilon, Gregory J. Riely, Danielle Murphy, Tiziana Usari, D. Ross Camidge, Miyako Satouchi, Paul K. Paik, Sherry Li, Mark M. Awad, Toyoaki Hida, Jared Weiss, Rebecca S. Heist, Hidetoshi Hayashi, Sherry C. Wang, Benjamin Solomon, Sai-Hong Ignatius Ou, Keith D. Wilner, Gregory A. Otterson
Publikováno v:
Nature medicine
MET exon 14 alterations are oncogenic drivers of non-small cell lung cancers (NSCLCs).1 These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition.2 Crizotinib is a multikinase inhibitor with potent act
Autor:
Takumi Kishimoto, Yutaro Kaneko, Toyoaki Hida, Yuichiro Ohe, Masayuki Takeda, Masayuki Yamada, Kazuhiko Nakagawa, Chikao Morimoto, Hidehito Horinouchi, Junichi Shimizu, Takashi Seto, Itaru Miyashita, Kaname Nosaki
Publikováno v:
Lung Cancer. 137:64-70
Objectives CD26 is a transmembrane glycoprotein with dipeptidyl peptidase IV activity that is overexpressed in malignant pleural mesothelioma (MPM). We performed a phase I study to determine the maximum tolerated dose, pharmacokinetics, and antitumor
Autor:
Takashi Kijima, Hiroshi Tanaka, Kazuhiko Nakagawa, Keisuke Aoe, Mitsuhiro Takenoyama, Morihito Okada, Toshiaki Takahashi, Yuichiro Ohe, Yuichiro Takeda, Toyoaki Hida, Terufumi Kato, Yoshinobu Namba, Fumio Imamura, Satoshi Oizumi, Jun Hirano, Kuninobu Kanai, Nobukazu Fujimoto
Publikováno v:
Clinical Cancer Research. 25:5485-5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of ni
Autor:
Yilian Lin, Antonio Rossi, D. Ross Camidge, Nicolas Guibert, Massimo Di Maio, Anyi Xu, Toyoaki Hida, Chengchu Zhu, Sijia Ren, Raffaele Califano, Jianfei Shen
Publikováno v:
Transl Lung Cancer Res
Objective This review summarizes the current status of neoadjuvant therapy and discusses the choice of new clinical research endpoints for non-small cell lung cancer. Background Neoadjuvant chemotherapy is a recognized practice in patients with resec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81ae10822712474a21ae31e37363aa7c
https://europepmc.org/articles/PMC8350086/
https://europepmc.org/articles/PMC8350086/
Autor:
Jian Hu, Zhaohui Fan, Qi-Xun Chen, Yi Zhang, Qingchen Wu, Satoshi Watanabe, Yang Liu, Jiaqing Xiang, Hecheng Li, Junqiang Fan, Hao Zhang, Junji Uchino, Wen-Xiang Wang, Xiao-Jie Pan, Haitao Ma, Hui Tian, Ben G. L. Vanneste, Nai-Quan Mao, Toyoaki Hida, Yun-Chao Huang, Takeo Nakada, Bin Qiu, Dirk De Ruysscher, Qiang Li, Kaican Cai, Hao Long, Qingquan Luo, Jie Jiang, Hongxu Liu, Wei-Dong Hu, Stefano Bongiolatti, Shinji Sasada, Tao Jiang, Chun Chen, Raffaele Califano, Fengwei Tan, Jie He, Peng Zhang, Lunxu Liu, Jun Chen, Nobuhiko Seki, Kenneth W. Merrell, Jun-Feng Liu, Zhenfa Zhang, Federico Cappuzzo, Sai Yendamuri, Pierfilippo Crucitti, Haruhiko Sugimura, Paul Hofman, Nan Wu, Gening Jiang, Yongde Liao, Chao Cheng, Shugeng Gao, Julian R. Molina, Li Wei, Lijie Tan, Giulio Metro, In-Jae Oh, Yusuke Tomita, Wenjie Jiao, Yuming Zhu, William C. Cho, Stefania Rizzo, Lanjun Zhang, Mariano Provencio, Sang-Won Um, Jessica C. Sieren, Ke-Neng Chen, Said Dermime, Dong Wang, Shidong Xu, Lin Yang, Kunshou Zhu, Tian-Yang Dai, Kye Young Lee, Filippo Longo, Muhammad Furqan
Publikováno v:
Transl Lung Cancer Res
Translational Lung Cancer Research, 10(9), 3713-3736. AME Publishing Company
Translational Lung Cancer Research, 10(9), 3713-3736. AME Publishing Company
The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 de